Holen Sie sich die Stockscreener-App
1.81
4.02%
0.07
Handel nachbörslich:
1.81
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Head-To-Head Review: Dare Bioscience (NASDAQ:DARE) & Appili Therapeutics (OTCMKTS:APLIF) - Defense World
Maxim Group Upgrades Daré Bioscience (DARE) - MSN
Dare Bioscience, Inc. (DARE) reports Q4 loss, lags revenue estimates - MSN
Dare Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
Transcript : Daré Bioscience, Inc., 2025 Earnings Call, Mar 26, 2026 - marketscreener.com
Dare Bioscience, Inc. (DARE) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency By Investing.com - Investing.com India
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Daré Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DARE) 2026-03-26 - Seeking Alpha
Q4 2025 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience (NASDAQ: DARE) expands dual-path women’s health model - Stock Titan
Daré Bioscience (NASDAQ: DARE) details 2025 loss, funding boost and upcoming product launches - stocktitan.net
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Dare Bioscience FY 2025 earnings preview - MSN
Daré Bioscience, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
A Viagra ingredient is now in a topical cream developed for women - Stock Titan
On National Viagra Day, Women Finally Claim Their Turn: - ChartMill
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Daré Bioscience, Inc. to Host Conference Call on March 26, 2026, for Year-End Financial Results and Company Update - Quiver Quantitative
Daré Bioscience schedules March 26 webcast for 2025 results - stocktitan.net
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com Australia
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
Daré Bioscience extends NIH grant period for preterm birth drug By Investing.com - Investing.com Australia
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Dare Bioscience receives NIH funding extension for preterm birth treatment By Investing.com - Investing.com Australia
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - manilatimes.net
NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
Daré Bioscience Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) advances Regulation A unit offering - Stock Titan
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Daré Bioscience Announces FDA Clearance of IND for Phase 2 - GlobeNewswire
New vaginal insert targets virus behind nearly all cervical cancers - Stock Titan
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):